Suppr超能文献

丝氨酸蛋白酶抑制剂对体外骨吸收的影响。

The effects of serine proteinase inhibitors on bone resorption in vitro.

作者信息

Tumber A, Papaioannou S, Breckon J, Meikle M C, Reynolds J J, Hill P A

机构信息

Department of Orthodontics and Paediatric Dentistry, United Medical and Dental Schools of Guy's, King's and St Thomas' Hospitals, University of London, London SE1 9RT, UK.

出版信息

J Endocrinol. 2003 Sep;178(3):437-47. doi: 10.1677/joe.0.1780437.

Abstract

The aims of this study were to identify the role and sites of action of serine proteinases (SPs) in bone resorption, a process which involves a cascade of events, the central step of which is the removal of bone matrix by osteoclasts (OCs). This resorbing activity, however, is also determined by recruitment of new OCs to future resorption sites and removal of the osteoid layer by osteoblasts (OBs), which enables OCs to gain access to the underlying mineralized bone. The resorption systems we have studied consisted of (i) neonatal calvarial explants, (ii) isolated OCs cultured on ivory slices, (iii) mouse OBs cultured on either radiolabelled type I collagen films or bone-like matrix, (iv) bone marrow cultures to assess OC formation and (v) 17-day-old fetal mouse metatarsal bone rudiments to assess OC migration and fusion. Two separate SP inhibitors, aprotinin and alpha(2)-antiplasmin dose-dependently inhibited (45)Ca release from neonatal calvarial explants: aprotinin (10(-6) M) was the most effective SP inhibitor, producing a maximum inhibitory effect of 55.9%. Neither of the SP inhibitors influenced either OC formation or OC resorptive activity. In contrast, each SP inhibitor dose-dependently inhibited OB-mediated degradation of both type I collagen fibrils and non-mineralized bone matrix. In 17-day-old metatarsal explants aprotinin produced a 55% reduction in the migration of OCs from the periosteum to the mineralized matrix after 3 days in culture but after 6 days in culture aprotinin was without effect on OC migration. Primary mouse osteoblasts expressed mRNA for urokinase type plasminogen activator (uPA), tIssue type plasminogen activator (tPA), the type I receptor for uPA, plasminogen activator inhibitor types I and II and the broad spectrum serine proteinase inhibitor, protease nexin I. In situ hybridization demonstrated expression of tPA and uPA in osteoclasts disaggregated from 6-day-old mouse long bones. We propose that the regulation of these various enzyme systems within bone tIssue determines the sites where bone resorption will be initiated.

摘要

本研究的目的是确定丝氨酸蛋白酶(SPs)在骨吸收过程中的作用及作用位点。骨吸收是一个涉及一系列事件的过程,其中央步骤是破骨细胞(OCs)去除骨基质。然而,这种吸收活性还取决于新的破骨细胞向未来吸收位点的募集以及成骨细胞(OBs)去除类骨质层,这使得破骨细胞能够接触到下面的矿化骨。我们研究的吸收系统包括:(i)新生颅骨外植体;(ii)在象牙薄片上培养的分离破骨细胞;(iii)在放射性标记的I型胶原膜或骨样基质上培养的小鼠成骨细胞;(iv)用于评估破骨细胞形成的骨髓培养物;(v)用于评估破骨细胞迁移和融合的17日龄胎鼠跖骨雏形。两种不同的SP抑制剂,抑肽酶和α2-抗纤溶酶,剂量依赖性地抑制新生颅骨外植体中(45)Ca的释放:抑肽酶(10^-6 M)是最有效的SP抑制剂,最大抑制效果为55.9%。两种SP抑制剂均不影响破骨细胞的形成或破骨细胞的吸收活性。相反,每种SP抑制剂均剂量依赖性地抑制成骨细胞介导的I型胶原纤维和非矿化骨基质的降解。在17日龄的跖骨外植体中,抑肽酶在培养3天后使破骨细胞从骨膜向矿化基质的迁移减少了55%,但在培养6天后,抑肽酶对破骨细胞迁移没有影响。原代小鼠成骨细胞表达尿激酶型纤溶酶原激活剂(uPA)、组织型纤溶酶原激活剂(tPA)、uPA的I型受体、I型和II型纤溶酶原激活剂抑制剂以及广谱丝氨酸蛋白酶抑制剂蛋白酶nexin I的mRNA。原位杂交显示tPA和uPA在从6日龄小鼠长骨中分离的破骨细胞中表达。我们认为,骨组织内这些不同酶系统的调节决定了骨吸收起始的位点。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验